Last reviewed · How we verify
anti PD-1 with nab-paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
anti PD-1 with nab-paclitaxel (anti PD-1 with nab-paclitaxel) — Fudan University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti PD-1 with nab-paclitaxel TARGET | anti PD-1 with nab-paclitaxel | Fudan University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti PD-1 with nab-paclitaxel CI watch — RSS
- anti PD-1 with nab-paclitaxel CI watch — Atom
- anti PD-1 with nab-paclitaxel CI watch — JSON
- anti PD-1 with nab-paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). anti PD-1 with nab-paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-pd-1-with-nab-paclitaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab